Last reviewed · How we verify
Remifentanyl
Remifentanyl, marketed by Kocaeli University, is positioned in the acute postoperative pain segment. The drug's key strength lies in its mechanism of action, which is currently unspecified but likely contributes to its efficacy in managing postoperative pain. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Remifentanyl |
|---|---|
| Also known as | ultiva, Ultiva |
| Sponsor | Kocaeli University |
| Target | Mu-type opioid receptor, Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Acute postoperative pain
- General anesthesia
- Local anesthesia
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery (NA)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic Abdominal Surgery: A Randomized Controlled Trial (NA)
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Anesthesia Maintenance With Target-controlled Infusion of Propofol and Remifentanil at Fixed Ratio (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanyl CI brief — competitive landscape report
- Remifentanyl updates RSS · CI watch RSS
- Kocaeli University portfolio CI